The pronounced success of increased tech adoption in accelerating and streamlining clinical trials over the past few years has opened the floodgates for a slew of new technology and tactics
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh